PRAME family member 17 (PRAMEF17)

PRAME family member 17 is a protein encoded by the PRAMEF17 gene, part of the PRAME (Preferentially Expressed Antigen in Melanoma) family of cancer/testis antigens. This family consists of leucine-rich repeat proteins predominately expressed in testicular tissue and various tumors and is involved in immunity and reproductive processes. PRAMEF17 itself is predicted to act as a ubiquitin-like ligase-substrate adaptor, potentially functioning in protein degradation via the ubiquitin-proteasome system, and may be a component of the Cul2-RING ubiquitin ligase complex. However, PRAMEF17 is a relatively uncharacterized member, with no validated direct disease or drug interactions, and there is uncertainty in the literature regarding whether this gene is a pseudogene in some databases or actively codes for a functional protein in others. Most biological and clinical associations derive from the broader PRAME gene family, not this specific isoform[3][2][6][7][4]. Key notes and explanations: - is_target: PRAMEF17 itself is *not* currently considered a validated therapeutic target. It is associated with sinonasal undifferentiated carcinoma as a gene, but lacks evidence for direct targeting by drugs, clear disease mechanisms, or functional exploitation in therapy[3]. - is_incorrect: There is significant ambiguity in whether PRAMEF17 is protein-coding or a pseudogene (discrepant annotation in major resources), and its function is largely inferred from the parent family, not specific experimental data[2][3][4]. - disease_roles & function: Most data derive from the PRAME family. PRAME family proteins are widely researched as cancer/testis antigens due to their expression in tumors and role in cell cycle, but PRAMEF17-specific disease roles and functions are not established[7][3]. - drugs, biomarkers, mechanism: No validated drugs, biomarkers, or direct mechanisms specific to PRAMEF17 reported in current literature[3][4][6]. - description: The description synthesizes the family-level knowledge, but PRAMEF17-specific data is lacking. - aliases: Names as listed in Ensembl, HGNC, and protein databases[3][4]. - molecular_classifications: Based on structural predictions and PRAME family characteristics (Leucine-rich repeat proteins)[1][7]. If you are seeking information about a therapeutic target, general references to the *PRAME* protein (not PRAMEF17) may be far more relevant, as PRAME itself is a well-studied immunotherapy target and cancer-testis antigen. PRAMEF17 is a minor or poorly described member of this family, not currently a verified pharmacological or diagnostic target.

Other names

PRAMEF17OTTHUMG00000007909